{"filing":{"accession_number":"0001193125-26-257388","cik":"0001754068","ticker":"KLRS","company_name":"Kalaris Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"d85626d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/d85626d8k.htm"},"events":[{"id":6804,"run_id":5961,"accession_number":"0001193125-26-257388","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Kalaris Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing presents voting results for four matters: election of three Class III directors (Napoleone Ferrara, David Hallal, and Leone Patterson), advisory approval of named executive officer compensation, recommendation on frequency of future advisory compensation votes (approved for annual frequency), and ratification of Deloitte \u0026 Touche LLP as independent auditor. All votes passed with substantial majorities, making this a material shareholder vote results disclosure.","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4331,"accession_number":"0001193125-26-257388","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Kalaris Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing presents voting results for four matters: election of three Class III directors (Napoleone Ferrara, David Hallal, and Leone Patterson), advisory approval of named executive officer compensation, recommendation on frequency of future advisory compensation votes (approved for annual frequency), and ratification of Deloitte \u0026 Touche LLP as independent auditor. All votes passed with substantial majorities, making this a material shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:21.282007+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4331,"accession_number":"0001193125-26-257388","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Kalaris Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing presents voting results for four matters: election of three Class III directors (Napoleone Ferrara, David Hallal, and Leone Patterson), advisory approval of named executive officer compensation, recommendation on frequency of future advisory compensation votes (approved for annual frequency), and ratification of Deloitte \u0026 Touche LLP as independent auditor. All votes passed with substantial majorities, making this a material shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:57:21.282007+00:00","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-06-04"}]}